WASHINGTON, D.C. — The U.S. Food and Drug Administration has approved the nation's first blood test designed to help healthcare professionals diagnose Alzheimer's disease, marking a major milestone in neurological medicine and diagnostic innovation.

The newly approved test measures specific biological markers linked to Alzheimer's disease and is intended to support physicians when evaluating patients showing signs of cognitive decline. Until now, diagnosis has often relied on brain imaging or cerebrospinal fluid testing, both of which can be more invasive, expensive or less accessible.

Medical experts say the approval could improve access to earlier diagnosis, allowing patients and families to begin treatment planning and supportive care sooner. Earlier detection has become increasingly important as new Alzheimer's therapies are designed to slow disease progression during its early stages.

The FDA emphasized that the blood test should be used alongside comprehensive clinical evaluations rather than as a standalone diagnostic tool. Physicians are expected to consider patient history, neurological examinations and other medical assessments before confirming a diagnosis.

Healthcare providers believe the approval may also accelerate the adoption of precision medicine in neurology by making biomarker-based testing more widely available. Researchers have been working for years to develop reliable blood-based diagnostics that can identify Alzheimer's-related changes before severe symptoms emerge.

The approval comes as Alzheimer's disease continues to affect millions of Americans and remains one of the leading causes of disability among older adults. Improved diagnostic tools could also help researchers enroll patients into clinical trials earlier, potentially advancing future treatments.

Industry analysts say the decision represents a significant advancement for both the healthcare and biotechnology sectors, highlighting growing investment in innovative diagnostics and personalized medicine.

As healthcare systems continue expanding access to advanced neurological care, the FDA's approval of the first Alzheimer's blood test could transform how memory disorders are evaluated and managed across the United States.